

# Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>)

Patricia D Walshaw<sup>1</sup>  | Laszlo Gyulai<sup>2,3</sup> | Michael Bauer<sup>4</sup> | Mark S Bauer<sup>5</sup> | Brian Calimlim<sup>1,6</sup> | Catherine A Sugar<sup>1,6</sup> | Peter C Whybrow<sup>1</sup>

<sup>1</sup>Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, California, USA

<sup>2</sup>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA

<sup>3</sup>Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA

<sup>4</sup>Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

<sup>5</sup>Department of Psychiatry, VA Boston Healthcare System, Harvard Medical School & the Center for Healthcare Organization and Implementation Research, Boston, Massachusetts, USA

<sup>6</sup>Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles (UCLA), Los Angeles, California, USA

## Correspondence

Peter C. Whybrow, Department of Psychiatry & Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA, 760 Westwood Plaza, C7-463, Los Angeles, CA 90095, USA.  
Email: pwhybrow@mednet.ucla.edu

## Funding information

National Institute of Mental Health, Grant/Award Number: 1P01 MH44210-01

**Objectives:** This report describes the first comparative double-blind, placebo-controlled trial of levothyroxine (L-T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) as adjunctive treatments in rapid cycling bipolar disorder.

**Methods:** Thirty-two treatment-resistant, rapid cycling patients who had failed a trial of lithium were randomized into three treatment arms: L-T<sub>4</sub>, T<sub>3</sub>, or placebo. They were followed for ≥4 months with weekly clinical and endocrine assessments.

**Results:** There were no statistically significant differences between the groups in age, gender, duration of illness, or thyroid status. Markov chain analyses were employed to assess treatment effects on cycling patterns among mood states (euthymia, depression, mania, and mixed). *Within groups*, post-treatment the L-T<sub>4</sub> group spent significantly less time depressed or in a mixed state and greater time euthymic. The T<sub>3</sub> and placebo groups did not differ significantly pre- and post-treatment in any mood state, although the pattern of effects was the same for the T<sub>3</sub> group as for the L-T<sub>4</sub> group. *Between groups*, the L-T<sub>4</sub> group had a significantly greater increase in time euthymic and decrease in time in the mixed state than the placebo group. Other group differences were not significant, although they were in the expected direction.

**Conclusions:** The findings in this first double-blind study directly comparing the effects of L-T<sub>4</sub> and T<sub>3</sub> therapy against placebo provide evidence for the benefit of adjunctive L-T<sub>4</sub> in alleviating resistant depression, reducing time in mixed states and increasing time euthymic. Adjunctive T<sub>3</sub> did not show statistically significant evidence of benefit over placebo in reducing the time spent in disturbed mood states.

## KEYWORDS

bipolar disorder, levothyroxine, rapid cycling, thyroid, triiodothyronine

## 1 | INTRODUCTION

Rapid cycling is the most malignant variant of bipolar disorder, affecting some 25–43% of those with bipolar illness.<sup>1</sup> The rapid cycling phenotype has been defined as four or more mood episodes

per year.<sup>2</sup> However, many individuals experience more frequent episodes, with approximately two-thirds having four to 11 per year, and with nearly all of those having 12 or more episodes being female.<sup>3,4</sup> Rapid cycling has a refractory clinical course and is commonly associated with greater work impairment, alcohol abuse, more frequent

suicide attempts, and lower response to standard pharmacological treatment than bipolar disorder in general.<sup>5,6</sup>

Therapeutic intervention is complex. The majority of individuals with rapid cycling bipolar disorder are treatment-resistant and the literature on controlled studies of pharmacologic intervention is sparse. A PubMed search in November 2017 employing the key words “rapid cycling,” “rapid-cycling,” “bipolar,” and “randomized” yielded only 12 randomized controlled trials of pharmacologic treatment for rapid cycling, with the majority of other studies being open trials or post hoc analyses.<sup>7</sup>

An association between the thyroid economy and bipolar disorder—and particularly rapid cycling—is evident from clinical and research studies. Patients with bipolar disorder are more likely to have thyroid abnormalities than healthy individuals.<sup>8,9</sup> Thyroid dysfunction is also associated with poor treatment response in bipolar depression<sup>10</sup> and mixed states.<sup>11</sup> In an early study of 30 patients with rapid cycling, 23% were found to have grade I hypothyroidism, while 27% had grade II and 10% grade III.<sup>12</sup> While those individuals with rapid cycling bipolar disorder are disproportionately women,<sup>3</sup> findings could not be accounted for by the number of women in the study, or simply by the use of lithium carbonate, an anti-thyroid agent. These observations suggest that the development of hypothyroidism, regardless of etiology, may increase the risk of the rapid cycling variant in bipolar individuals. Subsequent studies have confirmed this.<sup>13-15</sup>

This association between the hypothyroid state and the rapid cycling bipolar phenotype first prompted the use of thyroid hormone as an adjunct to pharmacologic treatment in those individuals with refractory disease. In an open-label study, the addition of high-dose (supra-physiologic) levothyroxine (L-T<sub>4</sub>) to a stable therapeutic regimen of mood-stabilizing drugs in rapid cycling bipolar disorder was associated with improvements in depressive symptoms in 10 out of 11 patients and a reduction in manic symptoms in five out of seven patients.<sup>16</sup> These findings were replicated in five additional studies. Taking their findings together, these open-label studies reported an improved response rate of approximately 50%, especially in bipolar patients with resistant depression, when L-T<sub>4</sub> was given concomitantly with mood stabilizers.<sup>17-21</sup>

Emerging from these studies was also the observation that some patients responding to high-dose L-T<sub>4</sub> had no evidence of peripheral thyroid dysfunction. This suggested that in such patients, rather than simply “offsetting” a peripheral thyroid hormone deficit, the high doses of adjuvant L-T<sub>4</sub> were playing a “central” therapeutic role, directly impacting the brain-thyroid economy.<sup>22</sup> Subsequently, in an open-label trial of adjuvant high-dose L-T<sub>4</sub> in treatment-resistant, euthyroid bipolar patients, an improvement in depression scores was found that correlated with shifts in cerebral blood flow as measured by positron emission tomography.<sup>23</sup> These studies were confirmed in a double-blind placebo-controlled study of L-T<sub>4</sub> in bipolar depressed patients.<sup>24</sup>

The use of triiodothyronine (T<sub>3</sub>) as an adjunct in bipolar illness has been less studied. However, in a retrospective chart review of 159 treatment-refractory patients with diagnoses of bipolar II or


bipolar disorder not otherwise specified (NOS) who were treated with T<sub>3</sub>, 84% had improvement in depression symptoms and 33% had full remission of their illness.<sup>25</sup>

The present study compared L-T<sub>4</sub> and T<sub>3</sub> in bipolar illness, building on these earlier reports. It is the first double-blind placebo-controlled trial of adjuvant thyroid hormone treatment in lithium-refractory rapid cycling bipolar patients. It is also unique in that no study has tested head-to-head the effects of adjunctive L-T<sub>4</sub> against T<sub>3</sub> and placebo. The goal of the study was to determine whether L-T<sub>4</sub> and T<sub>3</sub> are of prophylactic value in reducing episodes of illness in rapid cycling bipolar patients refractory to lithium carbonate and, if so, how they compare to one another. The criteria for improvement focused upon a four-state mood model—specifically whether there was a reduction in the time spent in depressed, mixed, and/or manic states and, correspondingly, an increase in the proportion of time spent euthymic. We were interested both in within-group changes, in the percentage of time spent in each state from pre- to post-treatment, and in whether those changes differed by treatment arm.

## 2 | METHODS

### 2.1 | Patients

Patients were enrolled in the Bipolar Clinic within the Department of Psychiatry at the University of Pennsylvania. The study received University of Pennsylvania Institutional Review Board approval prior to enrolling patients. Patients between the ages of 18 and 65 years who indicated a willingness to participate had the study procedures explained and completed written informed consent before being evaluated for possible participation using the Structured Clinical Interview for DSM-III-R.<sup>26</sup> Participants met criteria for bipolar disorder by DSM-III-R and/or Research Diagnostic Criteria, as well as the Dunner-Fieve criterion<sup>2</sup> for rapid cycling (four or more mood episodes per year) for the 12 months prior to study entry. For those patients cycling within hours or days, the symptom duration criteria during episodes were waived. Individuals met severity criteria with a score of  $\geq 15$  on the Hamilton Depression Rating Scale<sup>27</sup> (HDRS; 17 item) and  $\geq 7$  on the Young Mania Rating Scale<sup>28</sup> (YMRS), for depressed and (hypo) manic episodes, respectively. Patients with current substance abuse were excluded. Inclusion criteria also stipulated that all participants had failed to respond to treatment with lithium for their continued rapid cycling and were euthyroid. Patients remained on lithium throughout the study reported here. Other concomitant medications were stabilized upon entry and were not changed throughout the study follow-up period. Thirty-five individuals entered the study, with 32 participants comprising the final sample for analyses. One participant was lost to follow-up secondary to psychosocial difficulties unrelated to the study, and two were non-compliant with the protocol (Figure 1).



**FIGURE 1** Consolidated Standards of Reporting Trials (CONSORT) diagram

## 2.2 | Procedures and clinical measures

Upon study entry, participants underwent an evaluation that lasted at least through one mood cycle (during and into remission of depression, mania, or mixed state), or at least 1 month for the patients cycling most rapidly. During this prospective evaluation, patients were administered an assessment battery, neuroendocrine assessment at weekly clinic visits, and mood ratings (HDRS and YMRS). Then, participants were randomized into the three treatment arms: L-T<sub>4</sub>, T<sub>3</sub>, or placebo as an adjunct to their lithium treatment. For the L-T<sub>4</sub> group, dosage of levothyroxine was raised until the free T<sub>4</sub> index was between 4.5 and 7.5 units or until thyroid-stimulating hormone (TSH) suppression was reached (<0.1 units). For the T<sub>3</sub> group, dosage of triiodothyronine was titrated until serum levels for T<sub>3</sub>-resin uptake were between 0.65 and 1.36 units. In the control group, participants received increasing numbers of placebo capsules. The L-T<sub>4</sub> and T<sub>3</sub> groups were also supplemented with placebo capsules until all groups were taking six to eight capsules per day.

Scheduled weekly clinic visits throughout the trial included the clinical battery and neuroendocrine assessment. Outcome variables for analysis were measured starting 1 month after the achievement of desired serum iodothyronine levels and patients were then followed for at least 3 additional months. The only medication changes made

during this follow-up period were adjustments to maintain serum lithium concentration within a therapeutic range (0.8–1.2 mEq/L) and doses of benzodiazepine for agitation as needed. One physician, blind to the clinical state, had access to laboratory data and treatment assignment information to manage the medications. Other physicians completed all clinical assessments, without access to thyroid function indices or treatment assignment. Throughout the study, symptom severity was assessed using the HDRS and YMRS. In this study, the coefficient  $\alpha^{29}$  values for inter-rater reliability on the HDRS and YMRS were 0.94 and 0.82, respectively.

## 2.3 | Neuroendocrine assessment

Upon study entry, patients underwent a physical examination and laboratory assessment of thyroid function in order to document presence or absence of grade I or II hypothyroidism.<sup>30</sup> Patients who had been previously treated for hypothyroidism were not excluded. Seven individuals had a history of hypothyroidism. Five of the seven patients were on thyroid hormone replacement therapy and all were determined to be euthyroid upon study entry. Beginning in the prospective period and throughout the trial, participants received weekly serum thyroid hormone determination, including T<sub>4</sub>, T<sub>3</sub>-resin uptake, and TSH.

## 2.4 | Statistical assessment and analysis

The treatment arms were compared on baseline clinical and demographic factors using one-way analyses of variance for continuous variables and chi-squared tests for categorical variables. Because of the complexity of the mood data, encompassing multiple states along with significant inter-subject variability in phase and amplitude in these rapid-cycling patients, a Markov chain technique<sup>31</sup> with bootstrap re-sampling was used to test for longitudinal treatment effects, as explained below.

### 2.4.1 | Time periods

The data were divided into two time periods. The pre-treatment period encompassed measurements obtained prior to randomization. The post-treatment period began 4 weeks after TSH levels reached  $<0.1 \mu\text{IU/mL}$  for the L-T<sub>4</sub> group and when the T<sub>3</sub>-resin uptake was in the critical range for the T<sub>3</sub> group. To make the assessment windows comparable in length and spacing, for placebo patients the start of the post-treatment period was set to the median time to stabilization in the L-T<sub>4</sub> group (70 days).

### 2.4.2 | Treatment effect criteria


The primary outcome measures in this study were the HDRS and YMRS. We used these measures to assign subjects to mood states longitudinally, specifically euthymia, depression, mania, and mixed mania and depression. We then used a Markov chain approach to compare the week-to-week transition dynamics among these four mood states pre- and post-treatment. Markov chains allow one to assess the probability of moving from a single state to any other state and provide estimates of both the proportion of time spent in each state and the times between transitions, capturing precisely

the parameters of the rapid cycling process that are of interest in this comparative study. We assessed the overall dynamics of each treatment group for each study period and tested for changes in the distribution of time spent in each of the mood states from pre- to post-treatment, both within each study arm and differentially between treatment arms.


### 2.4.3 | Determining mood state sequences

We considered two important elements in making mood state assignments. The first consideration was in setting the appropriate thresholds corresponding to the different mood categories. We considered using absolute clinical cutoffs. However, not only were the patients in our sample treatment refractory, spending little time below the full clinical thresholds, but many also experienced considerable individual variation in symptom levels. Therefore, in order to be able to capture effectively treatment-related improvements that were potentially relevant for an individual patient, even when they did not meet clinical remission standards, we instead used the median scores of each patient's pre-treatment HDRS and YMRS assessments as their personal reference thresholds. By indexing to baseline we were effectively able to capture changes in the patterns of mood over time. We retained the state labels of euthymic, depressed, manic and mixed for interpretive convenience.

Secondly, the Markov chain approach requires state assignments at a common set of regularly spaced time intervals. We opted for a 1-week *chain time* since this was the schedule of the clinical visits. However, in practice, mood symptom measurements were somewhat unevenly spaced with an average separation of about 2 weeks. The original observations were therefore first linearly interpolated and then the mood states were assigned at weekly intervals using the interpolated values to create complete mood state sequences for each patient (Figure 2).



**FIGURE 2** Mood states were assigned at weekly intervals based on each individual's interpolated scores on HDRS and YMRS relative to their own pre-treatment median (as indicated by the grey lines)



**FIGURE 3** Individual mood state sequences were combined to estimate the transition matrices (i.e. probabilities of moving from any one state to any other state). The transition matrices were then used to calculate the long-run fraction of time participants would be expected to spend in each of the mood states under the specified treatment regimen. The pre-post differences in the stationary distributions were used to assess the treatment effects on euthymia, depression, mania, and mixed mood states

#### 2.4.4 | Calculating the transition matrices and the long-run stationary distributions

In a stationary Markov chain, subjects are assumed to move among a fixed set of states over time and that process is defined by a *transition matrix*, which gives the probability of staying in the current state or moving from it into any of the other states. The transition probabilities are assumed to be fixed and to depend only on a subject's current state (the *Markov property*). The diagonal elements of the transition matrix (which give the probability of remaining in the current state) can be used to calculate the expected duration of a mood state (higher probabilities mean longer durations). The transition matrix, as a whole, then can be used to calculate the *stationary distribution* of the chain, which gives the long-run (or steady-state) proportion of the time that subjects will spend in each of the mood states. For each treatment arm (placebo, T<sub>3</sub>, and L-T<sub>4</sub>), and treatment period (pre-randomization and post-stabilization), we estimated the transition matrix by pooling the corresponding patient mood state sequences and calculating the fraction of times those patients in a given state had moved to other states at the next week's evaluation. We then used those transition matrices to calculate the corresponding stationary distributions (Figure 3).


#### 2.4.5 | Assessing treatment effects

Changes in the long-run distributions from the pre-treatment to post-treatment period were used to assess treatment effects within each study group. Subsequently, the within-group changes were compared to test for differential treatment effects across the study groups. These analyses were performed for each mood state individually. Since the long-run proportion of time spent in each mood state does not have a standard distribution, to assess statistical significance of treatment effects we used a non-parametric technique called the *bootstrap*<sup>32</sup> whereby one repeatedly resamples observations from the original data set and recalculates the parameter or test statistic of interest to simulate its distribution and corresponding standard errors or confidence intervals. Here, we resampled subjects to appropriately preserve the transition structure, generating 10 000 bootstrap data sets, and calculated the appropriate *within* and *between* group differences for each one (Figures 4 and 5).


### 3 | RESULTS

#### 3.1 | Demographic and clinical data

No statistically significant differences between groups were observed for age, gender, bipolar disorder type, duration of illness, or



**FIGURE 4** Figure presents the observed values and smoothed histograms of the bootstrap distributions of the change in percentage time spent in each mood state from baseline to post-treatment within each study arm. The various colors correspond to the treatment arms (black = placebo, blue = T3, red = L-T4). The 0 point on the x-axis indicates where there was no pre-post change in time spent in a particular state. Distributions to the right of 0 indicate an increase in time spent in that state from pre- to post-treatment, while distributions to the left of 0 indicate a decrease in time spent in that state. The dashed lines are observed data estimates for each group. P-values were computed as % of extreme tail to 0, doubled for two-sided test



**FIGURE 5** The figure presents the observed values and smoothed histograms of the bootstrap distributions of the differential treatment effects on the percentage time spent in each mood state for each pair of study arms. The various colors correspond to the pairs (blue = T3 vs placebo, red = L-T4 vs placebo, green = LT4 vs T3). The 0 point on the x-axis corresponds to no difference between the groups in pre-post change in time spent in a particular state. Values to the right of 0 indicate a greater increase (or smaller decrease) in time spent in that state in the first treatment group vs the second, while distributions to the left of 0 indicate a greater decrease (or smaller increase). The dashed lines are observed data estimates for each group comparison. P-values were computed as the % of the extreme tail to 0, doubled for a two-sided test

other clinical variables (Table 1). The durations of pre-treatment, stabilization, and post-treatment maintenance periods for each group are described in Table 2. Patients remained in the post-treatment phase of the study for a minimum of 3 months, although most were followed for longer (4-11 months). One patient was removed from

the study at 8 weeks post-treatment (T<sub>3</sub> group) for an episode of tachycardia, but the data were included in the analysis. Side effects in general were minimal (Table 2) and, with the exception of the patient noted above, did not cause individuals to withdraw from the study.

**TABLE 1** Demographics and baseline clinical characteristics

	L-T <sub>4</sub> (n = 13)	T <sub>3</sub> (n = 10)	Placebo (n = 9)
Age (years), mean (SD)	35.62 (9.88)	37.4 (7.07)	35.44 (9.08)
Duration of illness (years), mean (SD)	12.09 (11.67)	13.89 (7.96)	14.63 (10.8)
Gender (% female)	M = 5, F = 8 (61.5)	M = 4, F = 6 (60)	M = 1, F = 8 (88.9)
Bipolar I/bipolar II	5/8	6/4	6/3
Co-morbid Axis I			
Anxiety	3	3	3
History of drug/ alcohol abuse / dependence	6	5	2
Co-morbid Axis II			
Co-medication (in addition to lithium)			
SSRI <sup>a</sup>	1	2	0
Tricyclic antidepressants	1	0	1
Bupropion	0	0	1
Benzodiazepine	6	3	3
Valproate	1	0	1
Levothyroxine	4	1	2
History of hypothyroidism	4	1	2

<sup>a</sup>SSRI, selective serotonin reuptake inhibitor.

Numbers of patients are shown in the table, unless otherwise specified.

**TABLE 2** Study characteristics

	L-T <sub>4</sub> (n = 13)	T <sub>3</sub> (n = 10)	Placebo (n = 9)
Median study period duration (weeks)			
Pre-treatment	11.7	12.2	14.0
Stabilization	10.7	6.8	10.7
Post-treatment maintenance	16.0	16.6	15.6
Side effects, n			
Diarrhea	5	3	5
Mild tremor	6	4	1
Polyuria	2	2	1
Polydipsia	1	2	2
Dry mouth	1	1	1
Hot flashes/sweating	4	1	0
Dizziness	3	0	0
Fatigue	3	1	2
Tachycardia	0	2	0
Mild palpitations	2	0	0

### 3.2 | Mood state analyses—Markov chain

The transition matrices and long-run stationary distributions are shown in Table 3. Sample estimates and bootstrap distributions were computed for both within-group change and between-group differences in treatment effects on the long-run fraction of time

spent in each of the four mood states and are shown in Figures 4 and 5, respectively.

*Within group results* indicated that in the post-treatment period the L-T<sub>4</sub> group spent significantly less time depressed (−18.1%,  $P = .022$ ) or in a mixed state (−13.3%,  $P = .031$ ) as compared to pre-treatment (Figure 3) and correspondingly showed a significant

**TABLE 3** Transition matrices and stationary distributions pre-randomization and post-treatment stabilization

Transition matrices		Transition matrices							
		Pre-randomization				Post-treatment stabilization			
		Euth	Dep	Manic	Mixed	Euth	Dep	Manic	Mixed
Placebo	Euth	0.677	0.161	0.161	0.000	0.688	0.094	0.188	0.031
	Dep	0.217	0.522	0.043	0.217	0.188	0.625	0.063	0.125
	Manic	0.129	0.065	0.677	0.129	0.087	0.022	0.826	0.065
	Mixed	0.042	0.167	0.083	0.708	0.040	0.080	0.000	0.880
T <sub>3</sub>	Euth	0.649	0.108	0.162	0.081	0.765	0.103	0.132	0.000
	Dep	0.172	0.586	0.034	0.207	0.308	0.577	0.000	0.115
	Manic	0.189	0.027	0.649	0.135	0.206	0.000	0.647	0.147
	Mixed	0.074	0.185	0.222	0.519	0.056	0.167	0.167	0.611
L-T <sub>4</sub>	Euth	0.448	0.276	0.241	0.034	0.846	0.057	0.081	0.016
	Dep	0.196	0.652	0.065	0.087	0.188	0.656	0.031	0.125
	Manic	0.049	0.073	0.707	0.171	0.123	0.014	0.822	0.041
	Mixed	0.033	0.167	0.233	0.567	0.154	0.077	0.231	0.538
Stationary distributions									
Placebo		0.277	0.219	0.237	0.268	0.212	0.146	0.281	0.360
T <sub>3</sub>		0.298	0.193	0.293	0.216	0.458	0.166	0.237	0.139
L-T <sub>4</sub>		0.147	0.291	0.353	0.209	0.478	0.110	0.336	0.076

Dep, depression; Euth, euthymia.

increase in the percentage of time euthymic (+33.1%,  $P = .022$ ). The estimated time spent in the manic state also decreased post-treatment but this change was not significant. The T<sub>3</sub> and placebo groups did not show significant changes from pre- to post-treatment in percentage of time spent in any of the mood states. However, it is worth noting that the estimated changes in the T<sub>3</sub> group followed the same pattern of effects as in the L-T<sub>4</sub> group, although the improvements were not as big. The placebo group appeared to spend a greater percentage of time in a mixed state during post-treatment although again this was not statistically significant (Figure 4).

*Between-group results* showed that those participants receiving L-T<sub>4</sub> had significantly greater gains in time spent euthymic than those in the placebo group (+33.1% vs -6.5%,  $P = .033$ ). They also showed greater improvement in terms of time spent in a mixed state than the placebo group (-13.3% vs +9.3%,  $P = .045$ ) and a trend towards having a greater reduction in time spent depressed than did the T<sub>3</sub> group (-7.2% vs -2.7%,  $P = .121$ ), although this latter effect did not reach significance. Participants in the T<sub>3</sub> group demonstrated a similar pattern of effect over placebo as the L-T<sub>4</sub> group for mixed state, although again this was not significant. The T<sub>3</sub> group, however, did not show the improvement in time spent euthymic that the L-T<sub>4</sub> group did, being similar to the placebo group in this regard. No between-group differences were observed in mania (Figure 5).

## 4 | DISCUSSION

This study of the rapid cycling phenotype in bipolar disorder is the first to compare the effects of L-T<sub>4</sub> and T<sub>3</sub> adjunctive therapy against

placebo in a double-blind design. The findings provide evidence for the beneficial effects of L-T<sub>4</sub> over placebo. In within-group analyses, adjunctive L-T<sub>4</sub> reduced the time spent in the depressed or mixed states and increased the time spent in euthymia. Moreover, the improvements in euthymia and mixed depression/mania were significantly greater in the L-T<sub>4</sub> than in the placebo group. Results from the present study did not provide significant evidence that T<sub>3</sub> adds benefit over placebo in reducing the time spent in disturbed mood states for these bipolar patients. Most of the effects observed, however, were in that direction, suggesting that an adjunctive benefit may exist, albeit smaller than that of L-T<sub>4</sub>. This needs to be further assessed in a larger study.

The L-T<sub>4</sub> findings are consistent with prior open-label research in high-dose adjunctive L-T<sub>4</sub> for bipolar patients.<sup>16</sup> They also complement the recent findings of a randomized placebo-controlled trial of adjunctive L-T<sub>4</sub> where reduction in depressive symptoms was associated with decreases in limbic network glucose metabolism as measured by positron emission tomography.<sup>33</sup> However, most of these previous studies focused principally on the improvement of depressive symptoms rather than mitigating the course of rapid cycling. Thus, the finding in this double-blind placebo-controlled study that L-T<sub>4</sub> may also reduce the time spent in mixed states is an important one.<sup>1</sup>

The study reported here has several limitations. First, due to the inherent challenges in studying this refractory population, the study is limited in its sample size. The original study was powered for  $N = 60$  (20 participants per group). Thus, the smaller sample limited our statistical analyses and potential questions we could answer

using the original statistical methods proposed (repeated measures analysis of variance [ANOVA]), which are precarious with respect to power. We therefore used a customized sophisticated suite of non-parametric statistical methods to obtain a more powerful assessment of treatment effects. While this was effective at the group level, the small sample size still prevented us from examining treatment effects at the individual level or looking at differences in individuals who entered the study with a history of hypothyroidism versus those who were euthyroid at entry. Also, we were not able to examine the comparative effects of L-T<sub>4</sub> and T<sub>3</sub> in men and women. Life-long sex differences in thyroid axis function, with women disadvantaged, are well documented and known to modify response to pharmacologic treatments. As noted in the Introduction, other placebo-controlled studies do support the conclusion that high-dose L-T<sub>4</sub> has particular benefit in women with treatment-resistant bipolar depression.<sup>24</sup>

The value of T<sub>3</sub> in bipolar illness is less clear, both from this study and in the literature. The advantages of adjunctive T<sub>3</sub> for women with *unipolar* depression, however, have been demonstrated.<sup>24</sup> A meta-analysis of six double-blind, placebo-controlled studies in unipolar depression revealed that administration of adjunctive T<sub>3</sub> *accelerated* the effects of tricyclic antidepressants, particularly for women.<sup>34</sup> T<sub>3</sub> has also been studied as an *augmentation* agent for patients with treatment-resistant unipolar depression. Evidence from a meta-analysis of eight studies suggested that T<sub>3</sub> *may* augment the response to tricyclic antidepressants in some patients, although results were inconsistent.<sup>35</sup> As yet, no one has prospectively examined the augmenting effects of T<sub>3</sub> in treatment-resistant bipolar depressed women, potentially an important next step for randomized investigation.

Taken together with previous reports, the results of this study underscore the intimate association between thyroid metabolism and the regulation of mood in bipolar illness, and emphasize the potential value of levothyroxine as an adjuvant agent in the treatment of rapid cycling bipolar disorder. This growing body of knowledge also confirms, in those with lithium-resistant bipolar illness, that evidence of peripheral hypothyroidism is not a necessary precondition for therapeutic response to supraphysiological doses of L-T<sub>4</sub>. In this study, while eight of the rapid cycling individuals had a history of hypothyroidism (four in the L-T<sub>4</sub> group, one in the T<sub>3</sub> group and three in the placebo group) and seven were on thyroid hormone replacement therapy (four in the L-T<sub>4</sub> group, one in the T<sub>3</sub> group and two in the placebo group), all were "euthyroid" in their peripheral thyroid economy upon entry into the protocol and all were treatment resistant. At the other end of the thyroid metabolic spectrum, others with no baseline hypothyroidism, or history of it, also improved with the administration of high-dose L-T<sub>4</sub>.

How may this conundrum potentially be explained? Our working hypothesis builds on evidence that the *central* brain-thyroid economy is independently and more precisely regulated than is the peripheral thyroid metabolism.<sup>36</sup> Does the patient with rapid cycling or resistant bipolar depression who responds to high-dose L-T<sub>4</sub>, but

who has normal peripheral thyroid indices at baseline testing, have a vulnerable and easily disrupted *central* thyroid economy? Further, does lithium, which is known to be an anti-thyroid agent and an inhibitor of the de-iodinase enzymes in the brain and pituitary, further burden central thyroid metabolism?<sup>37</sup> An earlier study from our group, of lithium challenge in 20 medication-free patients who presented to the clinic with the rapid cycling phenotype but with normal peripheral thyroid indices, lends some support to this hypothesis. When compared to an age- and sex-matched normal control group, similarly exposed to a 4-week course of lithium at therapeutic doses, a TRH challenge test at the end of the study period revealed latent hypothyroidism in the rapid cycling group of patients.<sup>22</sup>

In such patients, do changes in central brain-thyroid homeostasis modify the phenotypic expression of bipolar disorder, resulting in a continuous cycling pattern? Both thyroid disease and bipolar disorder are familial illnesses, with strong genetic loading. Rapid cycling is also a robust behavioral phenotype. Rapidly advancing genetic and genomic technologies and a dramatic reduction in the cost of genome-wide association studies now offer a promising opportunity to further pursue this question.<sup>38</sup>

Finally, in regards to methodology, we would note that this type of longitudinal study with multiple assessments is difficult to do, and particularly so in rapid cycling bipolar disorder. We also found that the study offered unique statistical challenges and novel techniques have been used in the analysis of these data. Despite these complexities, we believe the study, the first of its kind, is of importance in further establishing the value of the thyroid hormones in modifying the clinical course of refractory bipolar disorder.

In conclusion, based on the findings reported here, we believe that levothyroxine remains a viable adjunctive treatment in rapid cycling bipolar disorder. Further research into the molecular mechanisms underpinning its therapeutic action is warranted.

## DISCLOSURES

Dr. Walshaw reports no competing interests. Dr. Gyulai reports no competing interests. Dr. Michael Bauer has received grant/research support from the Deutsche Forschungsgemeinschaft (DFG), European Commission (FP7), and Bundesministerium für Bildung und Forschung (BMBF), and the American Foundation for Suicide Prevention (AFSP). He has been a consultant for Janssen, Allergan and Lundbeck, and has received speaker honoraria from AstraZeneca, Lilly, Lundbeck, and Pfizer. Dr. Mark Bauer reports no competing interests. Dr. Calimlim receives salary from ICON plc. Dr. Sugar reports no competing interests. Dr. Whybrow reports no competing interests. Funding/support: this study was supported by National Institute of Mental Health Program Project Grant No. 1P01 MH44210-01 (PCW and MSB). Data collection for this study ended in 1998 and therefore the study was not registered in a clinical trials database.

## ORCID

Patricia D Walshaw  <http://orcid.org/0000-0002-4080-595X>

## REFERENCES

1. Carvalho AF, Dimellis D, Gonda X, Vieta E, McIntyre RS, Fountoulakis KN. Rapid cycling in bipolar disorder: a systematic review. *J Clin Psychiatry*. 2014;75:578-586.
2. Dunner D, Fieve R. Clinical factors in lithium carbonate prophylaxis failure. *Arch Gen Psychiatry*. 1974;30:229-233.
3. Whybrow PC. Sex differences in thyroid axis function: treatment implications for affective disorders. *Depression*. 1995;3:33-42.
4. Bauer M, Glenn T, Pilhatsch M, Pfennig A, Whybrow PC. Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. *Bipolar Disord*. 2014;16:58-71.
5. Cruz N, Vieta E, Comes M, Haro JM, Reed C, Bertsch J. EMBLEM advisory board: rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe. *J Psychiatr Res*. 2008;42:1068-1075.
6. Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. *Acta Psychiatr Scand*. 2003;108:4-14.
7. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. *Bipolar Disord*. 2013;15:115-137.
8. Krishna VN, Thunga R, Unnikrishnan B, et al. Association between bipolar affective disorder and thyroid dysfunction. *Asian J Psychiatr*. 2013;6:42-45.
9. Ozsoy S, Mavili E, Aydin M, Turan T, Esel E. Ultrasonically determined thyroid volume and thyroid functions in lithium-naïve and lithium-treated patients with bipolar disorder: a cross-sectional and longitudinal study. *Hum Psychopharmacol*. 2010;25:174-178.
10. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. *Am J Psychiatry*. 2002;159:116-121.
11. Chang KD, Keck PE, Stanton SP, McElroy SL, Strakowski SM, Geraciotti TD. Differences in thyroid function between bipolar manic and mixed states. *Biol Psychiatry*. 1998;43:730-733.
12. Bauer MS, Whybrow PC, Winokur A. Rapid-cycling bipolar affective disorder: I association with grade I hypothyroidism. *Arch Gen Psychiatry*. 1990;47:427-434.
13. Kusalic M. Grade II and grade III hypothyroidism in rapid-cycling bipolar patients. *Neuropsychobiology*. 1992;25:177-181.
14. Oomen HA, Schipperijn AJ, Drexhage HA. The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. *Clin Endocrinol*. 1996;45:215-223.
15. Zhang ZJ, Qiang L, Kang WH, et al. Differences in hypothyroidism between lithium-free and -treated patients with bipolar disorders. *Life Sci*. 2006;78:771-776.
16. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorders. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. *Arch Gen Psychiatry*. 1990;47:435-440.
17. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. *Neuropsychopharmacology*. 1994;10:183-189.
18. Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment refractory depression with high-dose thyroxine. *Neuropsychopharmacology*. 1998;18:444-455.
19. Bauer M, Berghöfer A, Bschor T, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. *Neuropsychopharmacology*. 2002;27:620-628.
20. Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. *Biol Psychiatry*. 1999;2:229-233.
21. Spooov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation—a pilot study. *J Affect Disord*. 1998;49:235-239.
22. Gyulai L, Bauer M, Bauer MS, García-España F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid cycling bipolar disorder after lithium challenge. *Biol Psychiatr*. 2003;53:899-905.
23. Bauer M, London ED, Rasgon N, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. *Mol Psychiatry*. 2005;10:456-469.
24. Stamm TJ, Lewitzka U, Sauer C, et al. Supraphysiological doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2014;75:162-168.
25. Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. *J Affect Disord*. 2009;116:222-226.
26. Spitzer R, Williams J, Gibbon M. *Structured Clinical Interview for DSM-III-R*. New York, NY: New York Psychiatric Institute; 1986.
27. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960;23:56-62.
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry*. 1978;133:429-435.
29. Nunally J. *Psychometric Theory*, 2nd edn. New York, NY: NY, McGraw-Hill International Book Co; 1978.
30. Wenzel K, Meinhold H, Raffenberg M, Adlkofer F, Schleusener H. Classification of hypothyroidism in evaluating patients after radioiodine therapy by serum cholesterol, T<sub>3</sub>-uptake, total T<sub>4</sub>, FT<sub>4</sub>-index, total T<sub>3</sub>, basal TSH, and TRH test. *Eur J Clin Invest*. 1974;4:141-148.
31. Taylor HM, Karlin S. *An Introduction to Stochastic Modeling*, 3rd edn. San Diego, CA: California, Academic Press; 1998.
32. Efron B, Tibshirani RJ. *An Introduction to the Bootstrap*. New York, NY: Chapman & Hall; 1993.
33. Bauer M, Berman S, Stamm T, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. *Mol Psychiatry*. 2016;21:229-236.
34. Altshuler L, Bauer M, Frye M, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. *Am J Psychiatry*. 2001;158:1617-1622.
35. Aronson R, Offman HJ, Joffe RT, Naylor D. Triiodothyronine augmentation in the treatment of refractory depression. A Meta-Analysis. *Arch Gen Psychiatry*. 1996;53:842-848.
36. Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. *J Neuroendocrinology*. 2008;20:1101-1114.
37. St. Germain D. Regulatory effect of lithium on thyroxine metabolism in murine neural and anterior pituitary tissue. *Endocrinology*. 1987;120:1430-1438.
38. Flint J, Munafo M. Schizophrenia: genesis of a complex disease. *Nature*. 2014;511:412-413.

**How to cite this article:** Walshaw PD, Gyulai L, Bauer M, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>). *Bipolar Disord*. 2018;00:1-10. <https://doi.org/10.1111/bdi.12657>